Trial Profile
Risk of thromboembolic events in elderly patients receiving intravitreal ranibizumab or bevacizumab for age-related macular degeneration or macular oedema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Nov 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- 25 Nov 2015 New trial record